Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewGenIvf Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewGenIvf Group's regulatory disclosures and financial reporting.
NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd executive Fong Hei Yue Tina, who serves as Chief Marketing Officer and director, has filed a Form 3 reporting beneficial ownership of 39 Class B Ordinary Shares. This filing reflects an initial statement of holdings, with no buy or sell transactions indicated in the data.
NewGenIvf Group Ltd director files initial ownership report. Director Ching Chan Florianna Ann Chi Wan submitted a Form 3 as an insider of NewGenIvf Group Ltd. The filing reports no insider transactions, exercises, gifts, or restructurings and serves only as an initial statement of beneficial ownership.
NewGenIvf Group Ltd director Tam Chun Wa submitted an initial ownership report on Form 3. The filing lists Tam Chun Wa as a director of the company but does not report any share purchases, sales, or other insider transactions.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.